OHPAS
Technology platformADC linker technology designed for stability in blood and selective drug release inside tumors.
FROM PUBLIC EVENTS · 2026-11-18
Early clinical · first deals Dosed the first patient with its B7-H3 ADC and signed a definitive ADC platform agreement with Samsung Bioepis.
Roles often seen at this stageResearch & development · Clinical & PV · BD & licensing
Develops antibody-drug conjugate (ADC) platform technologies, such as the OHPAS linker that keeps the drug stable in blood and releases it inside cancer cells, and its own ADC candidates.
ADC linker technology designed for stability in blood and selective drug release inside tumors.
ADC targeting B7-H3, in a Phase 1a trial at three major Korean hospitals in patients with solid tumors after standard therapy.
New payload technology; the company reported more than four times the tumor suppression of Enhertu at the same dose in an outsourced preclinical study.
Signed a definitive ADC platform agreement with Samsung Bioepis for the first target.
Dosed the first patient in the Phase 1 trial of ITC-6146RO.
Official role guide
Observed 2026-11-18
Information from a role guide does not establish a current vacancy.
A brief based on selected official material, not an exhaustive product or vacancy list.